HCP (HCP) : Zacks Investment Research ranks HCP (HCP) as 2, which is a Buy recommendation. 1 other analysts are mildly bullish on the stock and favor a Buy. Not everyone is convinced about the stocks future, hence, the stock receives 1 Sell recommendation. 2 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 9 research analysts is 3.37, which indicates as a Hold.
HCP (HCP) stock is expected to deviate a maximum of $6.26 from the average target price of $31.29 for the short term period. 7 Street Experts have initiated coverage on the stock with the most promising target being $43 and the most muted being $23.
HCP (NYSE:HCP): The stock opened at $35.62 on Wednesday but the bulls could not build on the opening and the stock topped out at $35.77 for the day. The stock traded down to $35.12 during the day, due to lack of any buying support eventually closed down at $35.53 with a loss of -0.56% for the day. The stock had closed at $35.73 on the previous day. The total traded volume was 2,768,503 shares.
Also, Morgan Stanley downgrades its rating on HCP (NYSE:HCP). The global brokerage major maintains a current price target of $32 per share. Analysts at the Morgan Stanley have a current rating of Underweight on the shares. The shares were previously rated Equal-weight. The rating by the firm was issued on June 22, 2016. The company shares have dropped -5.65% from its 1 Year high price. On Aug 19, 2015, the shares registered one year high at $40.90 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $33.97 and the 200 Day Moving Average price is recorded at $33.82.
HCP, Inc. (HCP) is a real estate investment trust (REIT). The Company invests in real estate serving the healthcare industry in the United States. Its portfolio consists of investments in various healthcare segments: senior housing, post-acute/skilled nursing, life science, medical office and hospital. Its portfolio includes owned portfolio, unconsolidated joint ventures, and developments and redevelopments. Its owned portfolio includes around 1,040 properties under lease and 68 operating properties. It has interests in unconsolidated joint ventures representing around 88 properties in its senior housing, life science and medical office segments. It has assets under development, redevelopment and land held for future development in life science and medical office segments. The properties owned by it in medical office and senior housing segments, which are under development or redevelopment include Pacific Corporate Park, Memorial Hermann, Sky Ridge, Bayfront, Folsom and Deer Park.